tradingkey.logo

Oncology Institute Inc

TOI
View Detailed Chart

3.240USD

+0.250+8.36%
Close 09/18, 16:00ETQuotes delayed by 15 min
302.23MMarket Cap
LossP/E TTM

Oncology Institute Inc

3.240

+0.250+8.36%
Intraday
1m
30m
1h
D
W
M
D

Today

+8.36%

5 Days

+2.21%

1 Month

-19.80%

6 Months

+291.45%

Year to Date

+948.54%

1 Year

+980.00%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
48 / 72
Overall Ranking
257 / 4723
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
7.000
Target Price
+133.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 55.82% year-on-year.
Undervalued
The company’s latest PE is -4.46, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 39.72M shares, decreasing 33.08% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 4.28M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at 83 clinic locations across 15 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion and dispensary, radiation, programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. It also provides management services to 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
Ticker SymbolTOI
CompanyOncology Institute Inc
CEODr. Daniel Virnich, M.D.
Websitehttps://theoncologyinstitute.com/
KeyAI